KYMR 43.51 ▲ 3.10% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Kymera Therapeutics Inc.

    NASDAQ: KYMR · Real-Time Price · USD
    43.51
    1.31 (3.10%)
    At close: Sep 05, 2025, 3:59 PM
    43.51
    0.00%
    After-hours: Sep 05, 2025, 05:38 PM EDT
    3.10%
    Bid 40.43
    Market Cap 3.11B
    Revenue (ttm) 44.71M
    Net Income (ttm) -275.43M
    EPS (ttm) -3.4
    PE Ratio (ttm) -12.8
    Forward PE -10.45
    Analyst Buy
    Ask 46.22
    Volume 551,530
    Avg. Volume (20D) 723,193
    Open 42.88
    Previous Close 42.20
    Day's Range 42.73 - 44.00
    52-Week Range 19.45 - 53.27
    Beta 2.18

    About KYMR

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol KYMR
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for KYMR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Kymera Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    4 weeks ago
    -7.24%
    Kymera Therapeutics shares are trading lower after... Unlock content with Pro Subscription
    2 months ago
    -1.42%
    Kymera Therapeutics shares are trading lower after the company announced a $250 million public offering.
    news image

    5 days ago · seekingalpha.com

    Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript

    Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jare...

    news image

    4 weeks ago · seekingalpha.com

    Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript

    Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2025 Earnings Conference Call August 11, 2025 8:30 AM ET Company Participants Bruce N. Jacobs - Chief Financial Officer Jared A.

    news image

    3 weeks ago · zacks.com

    Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

    Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.58 per share a year ago.

    news image

    1 month ago · zacks.com

    Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · zacks.com

    Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

    KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.

    news image

    2 months ago · zacks.com

    KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

    Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.

    news image

    2 months ago · proactiveinvestors.com

    Gilead partners with Kymera to develop novel cancer therapy

    Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cy...

    news image

    2 months ago · reuters.com

    Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

    Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.

    news image

    2 months ago · businesswire.com

    Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

    FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive opt...

    news image

    2 months ago · marketbeat.com

    Analysts Can't Get Enough of These Little-Known Biopharma Stocks

    The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical ...

    Add to Watchlist